Stage IV HER2-Positive Breast Cancer: Leftfootforward's Survivor Story

Patient Info: Leftfootforward, Female, Under 40 | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Brain | Liver

Leftfootforward was diagnosed with Stage IIB HER2-positive breast cancer in 2010 and metastatic brain/liver disease in 2012; after systemic therapy, Gamma Knife, craniotomy for necrotic tissue, partial liver lobectomy, and resumed Herceptin, her latest scans showed no evidence of disease.

BreastCancer.org (ES)Read more →

How Learning To Ask For Help Can Make Life With MBC Easier

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: Not explicitly reported; HER2-targeted treatment with Herceptin and Tykerb reported

Metastatic Site: Brain; liver

Living with Stage IV metastatic breast cancer involving brain and liver; latest scans showed no evidence of disease, and she reported spending most of her Stage IV life in NED status.

breastcancer.orgRead more →

Triple-Negative Invasive Ductal Carcinoma: Katherine's Patient Story

Patient Info: Katherine Humphrey, Female, Under 40

Biomarkers: triple-negative

Recovering after bilateral mastectomy and additional chemotherapy, with capecitabine planned for fall 2026.

Dana-FarberRead more →

Rare Breast Neuroendocrine Cancer That Recurred in the Liver

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Chromogranin-positive; synaptophysin-positive; GATA-3-positive; ER-positive; PR negative on repeat biopsy and 40% positive on the mastectomy specimen; HER2-negative; Ki-67 85–95%

Metastatic Site: Liver; abdominal lymph nodes

After temporary responses to surgery and repeated chemotherapy, the cancer returned repeatedly in the liver and had spread to abdominal lymph nodes by May 2025. A new chemotherapy regimen was planned.

PubMed CentralRead more →

Stage IV HR-Positive Breast Cancer: Alison's Survivor Story

Patient Info: Alison, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Cervical/neck lymph nodes

Alison reported complete remission since August 2017 while continuing intermittent maintenance chemotherapy, most recently 1 month of treatment followed by 2 months off.

The Patient StoryRead more →

Non-metastatic metaplastic triple-negative breast cancer with residual disease after chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Metaplastic triple-negative breast cancer; HER2 0

The patient had an initial partial response to neoadjuvant chemotherapy but then progressed before surgery. Modified radical mastectomy found substantial residual metaplastic carcinoma with 0/21 nodes involved, followed by adjuvant radiotherapy and metronomic capecitabine.

PubMed CentralRead more →

Invasive lobular breast cancer with colonic metastases treated with colectomy and capecitabine

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Breast and colon metastatic samples were ER+ and HER2-; PR varied by sample

Metastatic Site: colon; perivisceral lymph nodes

After laparoscopic left colectomy and capecitabine for colonic metastases, follow-up showed no clinical or radiological evidence of recurrence or progression at 8 months postoperatively.

PubMed CentralRead more →

Metastatic triple-negative breast cancer with sacituzumab-govitecan pneumonitis and progression

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: lung

Sacituzumab-govitecan pneumonitis improved with corticosteroids and half-dose rechallenge did not reproduce pneumonitis, but follow-up CT showed one new pulmonary metastasis and enlargement of previous lung metastases; PFS on sacituzumab govitecan was 5.37 months.

PubMed CentralRead more →

Stage IV triple-negative invasive lobular breast cancer with HER2 mutations: complete metabolic response to trastuzumab deruxtecan

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Triple-negative invasive lobular breast cancer with HER2-low/dubious staining and HER2 FISH-negative; somatic ERBB2/HER2 and mutations.

Metastatic Site: iliac bone lesions / bone metastases

As of January 2026, metastatic triple-negative invasive lobular breast cancer with HER2 mutations had a sustained complete metabolic response to trastuzumab deruxtecan for 20 months, with dose reduction for neutropenia and no pulmonary toxicity.

PubMed CentralRead more →

Stage 3 triple-negative breast cancer complicated by immunotherapy endocrine toxicity

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: ER-negative; PgR-negative/PR-negative; HER2 0; Ki-67 70%; triple-negative breast cancer

After neoadjuvant therapy complicated by immune-related hypothyroidism, adrenal insufficiency, and suspected hypophysitis, surgery showed residual ypT1c ypN0 triple-negative disease. Pembrolizumab was stopped, adjuvant capecitabine was completed in June 2025, and endocrine replacement/follow-up continued.

PubMed CentralRead more →

Triple-negative breast pleomorphic adenocarcinoma: disease-free after mastectomy and one course of capecitabine

Patient Info: Anonymized, Female, 70+

Biomarkers: Triple-negative breast pleomorphic adenocarcinoma with PIK3CA mutation; markers supported the diagnosis.

As of September 2025, she had 2 years of disease-free survival after left total mastectomy, sentinel lymph node exploration, and 1 course of oral capecitabine.

PubMed CentralRead more →

HER2-positive breast cancer with brain, skin, and lymph-node metastases responding to dual-targeted therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: HER2-positive breast cancer. Initial tumor was ER/PR negative with Ki-67 30%; skin metastasis had Ki-67 70%.

Metastatic Site: brain, left cervical lymph nodes, skin of left chest…

After 1 cycle of inetetamab trastuzumab, pyrotinib, and capecitabine, skin metastases regressed, CEA and CA125 decreased, brain lesions shrank, and the largest lesion decreased by about 46%, meeting partial response; disease remained stable as of September 2024.

PubMed CentralRead more →

Recurrent breast cancer with pleural disease: capecitabine stopped after cardiac complications

Patient Info: Anonymized, Female, 50s | Stage IV

Metastatic Site: pleura

As of May 2025, she was living with recurrent breast cancer involving the pleura after stopping capecitabine because of major cardiac complications; cardiac symptoms were medically managed with stable NYHA class II dyspnea at 3-month follow-up.

PubMed CentralRead more →

Stage IV HER2-Positive Breast Cancer: Stephani's Survivor Story

Patient Info: Stephani St. Cyr, Female | Stage IV

Biomarkers: HER2-targeted treatments reported; no inherited cancer gene mutation found.

Metastatic Site: Bone; liver; brain

As of March 2025, Stephani had Stage IV metastatic breast cancer involving bone, liver, and brain, had no evidence of disease since July 2021, and continued HER2-targeted/systemic therapy.

Breast Cancer Recurring Years Later With Leptomeningeal Spread and a Brief Response to Trastuzumab Deruxtecan

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive, PR-positive, HER2-low

Metastatic Site: peritoneum, retroperitoneum, bones, leptomeninges

Died on May 10, 2024, about 18 years after her April 2006 breast-cancer diagnosis and about 6 years after metastatic recurrence.

PubMed CentralRead more →

Metastatic breast cancer with receptor evolution: sequential endocrine, immunotherapy, CDK4/6, and antibody-drug conjugate treatment

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Markers changed over time: initial tumor ER-positive/HER2-negative; local recurrence triple-negative/HER2-low; pleural fluid ER-negative.

Metastatic Site: mediastinal lymph nodes, pleura; pulmonary nodules…

More than 7 years after diagnosis, she remained on sequential systemic therapy for metastatic breast cancer, with at least a partial response 3 months after starting sacituzumab govitecan for presumed triple-negative pleural disease.

PubMed CentralRead more →

Paclitaxel-Related Macular Edema During Treatment for Metastatic Breast Cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive, HER2-negative

Cancer treatment continued with eribulin after paclitaxel was stopped because of vision toxicity in early 2021.

PubMed CentralRead more →

Stage 4 breast cancer: ongoing treatment with multi-line chemotherapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Initial tumor: hormone receptor-negative; HER2 2+. 2011 recurrence: ER 10%; PR 70%; HER2 2+.

Metastatic Site: pleura/pleural effusion; lung

Metastatic breast cancer with malignant pleural effusion achieved complete response after chemotherapy and long-term endocrine therapy; PET-CT in October 2023 still showed complete response, with ongoing cardiac and bone-health management.

PubMed CentralRead more →

Stage 4 luminal A breast cancer: tumor regression on hormone therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: skin, soft tissue, lungs

Metastatic Luminal A breast cancer involving skin/soft tissue and lungs showed regressing tumors and stable lung metastasis after 3 months of anti-hormone therapy plus capecitabine; longer-term control was not reported.

PubMed CentralRead more →

Stage II Breast Cancer Treatment Complicated by Scleroderma-Like Skin Changes

Patient Info: Anonymized, female, 50s | Stage II

Biomarkers: ER low-positive; PR-negative; HER2-negative

Her cancer remained stable during combination treatment. After morphea-like skin changes developed during therapy, treatment was modified and the skin condition improved 6 months after docetaxel was stopped.

PubMed CentralRead more →

Freezing treatment (cryoablation) used to manage slow-growing triple-negative breast cancer

Patient Info: Anonymized, Female | Stage Metastatic/Advanced

Biomarkers: ER-negative; PR-negative; HER2-negative; androgen receptor-positive in original tumor; Ki-67 5% initially and 10% at recurrence

At 29 months after recurrence diagnosis and 20 months after the first cryoablation, no viable breast tumor was seen at treated sites, axillary nodes were unchanged, pain was absent, and she remained active and independent.

PubMed CentralRead more →

HER2-Positive Metastatic Breast Cancer With Recurrent Severe Hypocalcemia - Case 2

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: bone, liver

She died about 7 years after her breast-cancer diagnosis after rapid deterioration from liver metastases.

PubMed CentralRead more →

Metastatic hormone receptor-positive breast cancer with paraneoplastic eosinophilic fasciitis

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: ER-positive; PR-positive; eosinophilia during paraneoplastic eosinophilic fasciitis flare

Metastatic Site: pelvis

As of February 2024, paraneoplastic eosinophilic fasciitis had remitted after prednisone plus systemic breast-cancer therapy, and 6-month follow-up showed no further skin recurrence or cancer progression.

PubMed CentralRead more →

Treatment-Refractory Triple-Negative Breast Cancer Treated With Tumor-Infiltrating Lymphocytes

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: Germline BRCA1 pathogenic variant; later triple-negative phenotype

Metastatic Site: skin, lungs, bones

Tumor burden briefly decreased after tumor-infiltrating lymphocyte therapy, but she developed severe treatment complications followed by rapid cancer relapse and died about 1 month after the TIL/IL-2 treatment began.

PubMed CentralRead more →